Objective The development of myeloid malignancies is a concern when administering thrombopoietin receptor (or the myeloproliferative leukemia virus proto-oncogene product, MPL) agonists. Progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia [AML, 9 (6.12%) AML patients among 147 MDS subjects] was reported in a clinical trial. However, only one (0.15%) case of AML among 653 immune thrombocytopenic purpura (ITP) subjects was reported. Our objective was to determine whether there is currently a safety signal in the FDA files termed Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) for AML in ITP patients who receive MPL agonists. Methods We conducted a case-controlled study using the FAERS as a source of case and control data. We compared demographic characteristics, such as gender, age and exposure to MPL agonists between AML patients and others among ITP subjects registered between 2002 and 2011. Results Total of 4,821 ITP subjects were identified, including 62 AML patients. The number of patients treated with romiplostim and eltrombopag was 54 (1.74%) AML patients among 3,102 ITP subjects and nine (1.52%) AML patients among 594 ITP subjects, respectively. It should be noted that all AML patients were exposed to one or more MPL agonists. Another factor associated with AML was male gender. Conclusion We herein report an association between AML and MPL agonist use in ITP subjects. Due to various biases and the incompleteness of the FAERS data, further studies are warranted to determine whether the detected signal is a real risk. Physicians should not alter their prescribing behaviors based on this single preliminary analysis.
Introduction
When human myeloproliferative leukemia virus protooncogene product (MPL) was first cloned, it was identified as a proto-oncogene of v-mpl, a truncated form of a cytokine receptor (1) . Originally v-mpl was recognized to be a viral oncogene that transforms myeloproliferative leukemia virus-infected hematopoietic progenitors (2) . Murine myeloblastic progenitors acquire growth factor independent proliferation on in vitro or in vivo infection of v-mpl (2-4). Since v-mpl alone is sufficient to promote leukemic transformation, activation of the MPL signal pathway is thought to play a role in leukemogenesis. Due to the mechanisms of action of thrombopoietin receptors (or MPL), one of the concerns regarding the use of these agonists is the potential adverse reaction of myeloid malignancy (5) . The risk of progression from myelodysplastic syndromes (MDS) to acute myelogenous leukemia (AML) has been observed in clinical trials of romiplostim (6) . The prescribing information for romiplostim states that a randomized, double-blind, placebocontrolled trial enrolling patients with severe thrombocytopenia and International Prognostic Scoring System (IPSS) low-or intermediate-1-risk MDS was terminated due to the increased number of cases of AML observed in the romiplostim treatment arm. At the time of an interim analysis, among 219 MDS patients randomized 2:1 to receive treatment with romiplostim or a placebo (147 romiplostim: 72 placebo), 11 patients exhibited progression to AML, including nine patients in the romiplostim arm (6.21% [95%CI; 2.83-11.3]) versus two patients in the placebo arm (2.78% [95%CI; 0. .68]). Moreover, Olnes et al. recently reported that as many as three of 25 aplastic anemia patients (12.0%[95%CI; 2.5-31.2%]) treated with eltrombopag developed clonal evolution, including two cases of monosomy 7 and one case of myeloid leukemia (7, 8) . Meanwhile, only one case of AML among 653 (0.15% [95%CI; 0.00-0.85]) immune thrombocytopenic purpura (ITP) subjects was reported in a cumulative analysis of clinical trials (http:www. info.pmda.go.jp/shinyaku/P201100020/index.html). Since the risk appeared to be relatively smaller in the ITP patients than in the MDS patients, there were no statistically significant differences between the study drug and placebo groups. Nevertheless, it is noteworthy that the patient who developed AML had been assigned to receive the study drug. Therefore, no statistically significant increases in the incidence of myeloid malignancies have been reported thus far in ITP patients treated with MPL agonists (5) .
We routinely run queries to detect signals of adverse reaction risks for whole drugs registered in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and happened to find various potential risks. Some of the detected signals are well known, such as myelosuppression associated with cytotoxic antineoplastic agents or hypoglycemia associated with human insulin or its derivatives. With respect to MPL agonists, we found AML, as well as myelofibrosis, including bone marrow reticulin fibrosis. During the routine queries, not insignificant proportions of patients with myelofibrosis were detected among those receiving romiplostim (2.54%[95%CI; 2.01-3.16]) and eltrombopag (3.81%[95%CI; 2.48-5.57]). An activating mutation of the MPL gene is associated with myelofibrosis rather than AML. In addition, prescriber information for MPL agonists recommends caution regarding the possibility for bone marrow reticulin fibrosis. Therefore, the signals detected for myelofibrosis appear to be relevant. As for AML, it is worth further analyzing the database because MPL agonists are approved for the treatment of ITP, not MDS. We herein further assess the signals of a risk of AML in ITP patients treated with MPL agonists.
Analyzing existing databases, such as the FAERS, can be quickly performed at an affordable cost. Spontaneous reporting databases can be viewed as sources of case and control data for case-controlled studies. However, due to the incompleteness and inconsistencies in spontaneous adverse event reporting, analyses of spontaneous reporting databases are usually regarded as being surrogates for controlled epidemiologic studies. This approach will provide hypotheses to interested scientists. Before conducting conventional controlled epidemiologic research, the use of preliminary and exploratory screening may be helpful, although screening may not yield conclusive results.
Our primary objective was to clarify whether the possibility of the development of AML in patients with ITP is worth further investigation. As a secondary objective, we herein describe the demographic characteristics of the AML patients registered in the database.
Materials and Methods

Study design
A case-controlled study comparing exposure to MPL agonists between patients with myeloid leukemia and a comparison group.
Setting
We used the Japan Pharmaceutical Information Center (JAPIC) AERS database, a version of the FAERS database whose data format was arranged by the JAPIC (Tokyo, Japan). Duplicates and multiple records, a well-known drawback of the FAERS (9), were excluded using a semiautomatic multistep process (10) . In order to detect and exclude as many as duplicates as possible in the database, an automated multistep process was applied. The process was carried out using a record-linkage strategy that groups records overlapping in four key fields: event date, patient age and sex and the reporting country, as previously reported (9, 10) . Records with three overlaps and just one missing datum were considered to be duplicates.
Subjects
We extracted ITP subjects by searching for their indication for therapeutic drug treatment in the FAERS between 2002 and 2011. The row data handling and basic tabulations were performed as previously reported (11) (12) (13) (14) (15) . In brief, the codes, "AUTOIMMUNE THROMBOCYTOPENIA," "IDI-OPATHIC THROMBOCYTOPENIC PURPURA " or "THROMBOCYTOPENIC PURPURA," coded according to the medical terminology for the safety database, called Med-DRA, were assumed to be used to register the ITP subjects. This extraction resulted in the identification of 4,821 ITP subjects after removing duplicate case IDs. Among the ITP subjects, we identified AML patients by searching for the terms, "ACUTE MYELOID LEUKAEMIA," "ACUTE MYELOID LEUKAEMIA (IN REMISSION) ," "ACUTE MYELOID LEUKAEMIA AGGRAVATED," "ACUTE MYELOID LEUKAEMIA NOS" and "ACUTE MYELOID LEUKAEMIA RECURRENT," in the adverse reaction fields of the FAERS. Among the 4,281 ITP subjects, there were 62 patients with AML. The control/comparison group consisted of the remaining ITP subjects. We compared the identified AML patients (cases) versus the subjects (non-cases) in the comparison group.
Analysis
The indicated numbers are the number of cases or noncases of the indexed conditions. The number of identified patients and comparison subjects was tabulated according to the reporting year, gender, age and drug. The reporting year was extracted from the reporting date, that is, the date received by the FDA. The demographic data are presented with the number of cases, unadjusted odds ratios (uaOR) with 95% confidence intervals (CIs) and p values calculated with two-sided Fisher's exact test in Table 1 . Due to the nature of spontaneous reports, the calculated p values are shown to highlight the differences in characteristics between the AML group and the comparison group; however, they are not intended to test statistical differences. The proportion (%) and 95% CI of cases of AML among the individual drugs used for ITP are tabulated in Table 2 . Table 2A shows the number of cases associated with each drug regardless of the concomitant use of other drugs. Table 2B shows the number of cases associated with a single agent or a combination of drugs. Variables identified to be associated with AML in the univariate analyses were further analyzed with an unconditional logistic regression model using the Rstatistical software package. There was an increase in the number of AML cases in the years 2010-2011 following the approval of MPL agonists as ethical pharmaceuticals in the USA. We did not place the reporting year in the proposed model to prevent multiple colinearity with the MPL agonists. In order to calculate the adjusted odds ratio, there must be a certain number of cases and controls. Since the number of cases was relatively small, we selected three drugs for the multiple logistic regression analysis based on the number of cases and individuals exposed to romiplostim, eltrombopag and prednisolone. Age was entered into the logistic regression model as a continuous variable with one increment of 10 years. Other variables were treated as logical variables, including gender (male=True, female=False) and drugs (exposure=True, no exposure=False). All combinations of variables were calculated for the Akaike's Information Criterion (AIC) value of the logistic regression models and then sorted according to the AIC value. We selected the model with the lowest AIC value among the models harbor- ing both MPL agonists as variables (Table 3) , because the objective of this analysis was to study the role of MPL agonists. We tested for confounding among factors, including age, gender and drugs. No confounding was detected, except between romiplostim and eltrombopag. We compared the residual error between the models in order to test for interactions one by one, and no interactions were detected. In one combination, we were unable to estimate the interaction because there were zero cells between romiplostim and eltrombopag. As a reference, we created one dummy case with AML without treatment with any of the MPL agonists in addition to the original dataset. The dataset with the dummy case did not indicate any interactions between romiplostim and eltrombopag. We believe that five variables compared to 62 events is a small enough number to avoid overfitting.
Missing data
The number of missing data is shown in Table 1 . Records with missing data were removed from the multiple logistic regression model. We constructed the model using the resulting 3,000 records.
Next, we tabulated the proportion of cases of AML among the patients treated with other drugs that are known to cause secondary AML. For this purpose, we created another dataset in which there were no restrictions regarding the indications for the use of the drugs. Drugs "known to cause secondary AML" were selected if their labels contained a warning of AML or its adverse reactions by searching the label database maintained by the Japanese health authority, the Pharmaceuticals and Medical Devices Agency (PMDA) (http://www.pmda.go.jp/). We tabulated the data to demonstrate the number and proportion of AML cases for each drug, as shown in Table 4 .
Results
A total of 4,821 subjects were identified as having ITP in the FAERS. We found 62 AML patients (1.29% [95%CI; 0.99-1.65]) among the ITP subjects. The remaining 4,759 subjects served as the comparison group. The ages (mean (SD)) of the AML and comparison groups were 66.4 (13.2) and 58.9 (21.5) years, respectively. All AML patients were treated with at least one MPL agonist. Among the comparison group subjects, the ages of the patients treated with and without MPL agonists were 62.3 (18.8) and 50.0 (25.1) years, respectively. There was a single peak in the sixties to seventies among the MPL agonist users, whereas there were two peaks around the teens and sixties to seventies in the comparison group. The younger peak in the comparison group most likely corresponds to patients with acute ITP. As shown in Table 1 . Since the number of individuals treated with eltrombopag was relatively small (n=594) compared to that treated with romiplostim (n=3,102), the calculated proportion was associated with a wider confidence interval. We also attempted to further investigate the effects of multiple medications. However, 4,337 (90.0%) of the 4,821 ITP subjects were treated with a single agent. Therefore, the combination use of drugs for ITP was limited, as shown in Table 2B .
We compared the proportion of cases of AML among the patients taking drugs that are "known to cause secondary AML" and MPL agonists. After searching the label database maintained by the PMDA, we found the following drugs: ranimustine, aclarubicin, mitoxantrone, idarubicin, busulfan, cytarabine, fludarabine, etoposide, lenograstim, cyclophosphamide, melphalan, actinomycin D, epirubicin, doxorubicin, nimustine, cladribine, filgrastim, mitomycin C, nelarabine, methotrexate, imatinib, azathioprine, temozolomide, nilotinib, tretinoin, dasatinib, interferon alpha, phenytoin, lapatinib, ethotoin, fosphenytoin, golimumab, live varicellazoster vaccine and mesna. We excluded the live varicellazoster vaccine from the tabulation because adverse reactions to vaccines are registered in another database called "VAERS," which is maintained by the US FDA and Centers for Disease Control and Prevention (CDC). In addition, we excluded mesna because this drug is used in combination with high-dose cyclophosphamide, which is known to cause secondary AML. As shown in Table 4 , among the 32 drugs that are known to cause secondary AML and the two MPL agonists, 25 (73.5%) drugs were antineoplastic drugs. Four drugs (12.5%) were cytokines, including two granulocyte colony-stimulating factors and the two MPL agonists. Three drugs (8.8%) were antiepileptic agents. The proportions of AML patients taking antiepileptic drugs and interferon were relatively small, although these drugs carry warnings in their prescribing information. On the other hand, the proportion of AML patients taking cytokines, including MPL agonists, was comparable to that of antineoplastic drugs.
Discussion
As shown in the results, some factors, including the use of romiplostim, were found to be associated with the development of AML in the ITP subjects. The number of adverse events, including AML and other adverse events (AEs), increased in 2010 and 2011 (Table 1 ), a few years after the approval of MPL agonists in 2008, which may be explained by the market penetration of MPL agonists after that event. This increase possibly suggests the duration of time to onset, although the dose in each subject and the duration between the use of the suspected drug and the onset of AML were not examined in detail in our study. Similarly, reporting from the USA was suggested to be a possible risk factor in a univariate analysis but not in a multivariate logistic regression analysis. Therefore, the high proportion of cases in the USA may reflect market penetration as well. In this analysis, an age between 60 and 69 years was identified as a possible risk factor in both a univariate and multivariate analysis. This finding may be affected by the peak ages of adult ITP (40-45 years) (16) and AML (70 years and older) (17) . Since the total number of AML cases was small, the number of cases in each group when analyzed according to age was very small. Therefore, the data of the high-risk age group should be interpreted with caution. Additionally, the higher incidence of reporting of AML in men is compatible with the gender distribution of the disease. The high incidence of AML in the elderly as well as men is also compatible with the distribution of de novo AML. These findings can be explained from the viewpoint of multistep pathogenesis based on the accumulation of various genetic alterations. Preleukemic individuals and those who have not yet developed AML but have accumulated genetic alterations exhibit a similar demographic distribution. The use of MPL agonists may possibly open the final gate, stimulating the development of AML in preleukemic individuals. Therefore, it is likely that MPL agonists play a role in these events. Since most cases of AML involve adults, the underlying ITP observed in this analysis was most likely chronic. This finding is compatible with the approved indications for the use of these drugs. Table 3 ). This difference between the two MPL agonists must have been due to a kind of artifact. The odds ratio reflects the relative number of each type of AE associated with a drug of interest versus the other drugs. Since the number of cases of AML and other types of AEs associated with romiplostim accounted for more than half of the database, the large number of AML cases associated with romiplostim decreased the odds ratio for eltrombopag. In other words, most cases of AML associated with romiplostim served as "AML cases associated with other drugs" in the calculation of the odds ratio for eltrombopag. Therefore, we think that both MPL agonists are similarly associated with the development of AML. Indeed, all AML patients were exposed to one or more MPL agonists.
From the time human MPL, which is known to be a proto-oncogene of v-mpl, a truncated form of a cytokine receptor (1), was first cloned, its potential oncogenicity has been a concern with respect to its therapeutic use. Initially, v-mpl was originally recognized to be a viral oncogene that transforms myeloproliferative leukemia virus-infected hematopoietic progenitors (2) . Since v-mpl alone is sufficient to promote leukemic transformation, activation of the MPL signal pathway is thought to play a role in leukemogenesis. Indeed, among 538 healthy volunteers evaluated in an early clinical study who received pegylated recombinant human thrombopoietin, an MPL agonist, three subjects developed B-cell malignancies. Although the incidence of malignancy was high, a causal relationship between the development of B-cell malignancy and the use of the study drug could not be established (18) . In addition to the clinical experience of myelodysplastic syndrome (6) and aplastic anemia (5, 8) described in the background of this paper, data supporting concerns regarding potential myeloid malignancy associated with MPL agonists have been accumulated with respect to MPL agonists and a natural ligand, thrombopoietin. In a report on mice induced to express murine thrombopoietin using a retrovirus vector, leukemic transformation of bone marrow cells was noted in two individual mice. It is not clear whether this transformation was caused by thrombopoietin exposure at a high concentration or mutagenesis induced by the retrovirus vector.
As shown in Table 4 , the proportion of cases of AML associated with MPL agonists was comparable to that of antineoplastic drugs. Since no drugs other than MPL agonists are usually used in the treatment of ITP, the underlying disease is quite different from that of patients treated with MPL agonists. Therefore, further interpretation of the data is difficult. However, it is noteworthy that cases of MPL agonists are required to be registered until December 2011. This processes is assumed to enhance reporting and increase the total number of reported adverse events. In other words, this condition may increase the denominators for MPL agonists and decrease the proportion of adverse events. Therefore, the calculated proportion of cases of AML associated with MPL agonists may be underestimated compared to that of other drugs. It is also noteworthy that the proportion of AML cases associated with drugs "known to cause AML". This means that a search of the FAERS would provide relevant information to some extent.
Additional findings were obtained from an analysis of hereditary thrombocytosis. As shown in Table 5 , two cases of myeloid leukemia (3.2%, [95%CI; 0.4-11.2]) including one case of AML (1.6%, [95%CI; 0.04-8.66]) were noted among 62 individuals with hereditary thrombocytosis whose pathogenesis was determined to involve the overexpression of thrombopoietin due to a gene mutation. Therefore, it is reasonable to be concerned that continuous exposure to thrombopoietin at a high concentration will promote leukemic transformation. Other studies have accumulated pedigrees of essential thrombocythemia patients with mutant c-MPL genes (Table 6 ). While the mechanisms by which the c-MPL mutations caused thrombocytosis in these cases are not entirely clear, the mutations were reported to be activated without the ligand. No cases of myeloid leukemia or AML (0.0%, [95%CI: 0.0-3.7]) were reported among 97 affected individuals listed in these pedigrees. Since there is a wide interval estimate due to the limited number of patients, this tabulation does not negatively influence the postulated concern.
By searching the FAERS database, we found a signal of the development of AML in ITP subjects treated with MPL agonists. One of the essential limitations of spontaneous reports is that the diagnosis of reported adverse events is not based on a predefined diagnostic criterion. However, the diagnosis of AML may be assumed to be generally reliable because ITP patients are diagnosed and treated by specialists in hematology who are assumed to be specialists in AML compared to general practitioners. Finally, our analysis is affected by various limitations of spontaneous reports conducted in postmarketing settings, such as underreporting, the effects of publicity and media attention and the temporal relationship between drug launch and the rate of reporting (19) (20) (21) (22) . Moreover, detailed information, such as the type of AML based on the FAB classification, is not included in the FAERS. Information such as the dose used in each subject or the duration between the use of the suspected drug and the onset of AML was also not examined in detail. Case-controlled studies conducted using spontaneous reporting databases are sometimes called 'disproportionality analyses.' When a spontaneous reporting database is viewed as the source of case and control data for a case-controlled study, then the reporting odds ratio (ROR) is an estimate of the relative risk (23) . This approach provides hypotheses or signals of risks for drugs. Due to the above mentioned limitations, the results may not be interpreted as results obtained Reference Year from controlled epidemiologic studies.
Conclusion
We found an association between the development of AML and the use of MPL agonists in ITP patients. As mentioned above, due to the limitations of spontaneous reporting, the data presented in this paper are not conclusive, but rather simply suggest a signal of a risk of AML. Further studies are warranted to determine whether the detected signal is a real risk. As a result, prescribing physicians should not alter their prescribing behavior based only on this preliminary analysis alone.
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